Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
GN.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HR.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HP.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GW.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GS.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XCF.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.34NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HY.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JC.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.105NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.9.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GM.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FT.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JD.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GJ.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HT.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JH.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CK.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.34.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.2.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JK.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23787.3US
EG.1.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.49NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBL.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FR.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.17NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.18.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22683US
B.1.578NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.544NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
B.1.448NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.425NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.354NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.503NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-21599.5US
B.1.36.31NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.623NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.214.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.588NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.210NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GM.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.44NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FU.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FV.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GJ.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used